Not many companies that have been around since the late 1800s can claim that they're growth companies. But Eli Lilly (LLY 0.82%) can. However, even growth stocks with long and impressive track records can see their share prices take a breather.Eli Lilly's stock is down about 6.4% over the last year through June 12. Some may worry about such a drop, but I don't believe that's a warning sign for investors. Rather, investors should think of this dip as a buying opportunity. Eli Lilly is gaining in weight lossE ...

以色列和伊朗之间的紧张局势加剧，全球股市遭重挫，道指跌超700 点。由于担心原油供应减少，原油价格飙涨、创2022年3月以来最大单日涨幅。避险情 绪则助推黄金收盘创新高，不过油价引发的通胀担忧短期压制避险买盘，美债收益率先跌后涨。 受以色列对伊朗发动袭击影响，美股开盘低开，随着冲突加剧，标普跌回6000点下方、道指跌近1.8%： 亚太时段，据央视新闻，当地时间13日凌晨，以色列对伊朗发动袭击。以伊冲突爆发在全球市场引发巨震，WTI原油一度暴涨超13%后回落，黄金等避险资 产明显拉升，全球股市集体下挫。 欧股盘中，央视报道，以色列称伊朗方面向以色列发射了100多架无人机。冲突加剧一度推动10年期美债收益率下行至4.31%。不过油价引发的通胀担忧压 制避险买盘，美债收益率随后悉数转涨，2年期和10年期美债收益率均上行超4个基点。 美股早盘，据央视，以色列袭击伊朗导致多国关闭领空，全球多地航空股下跌。标准普尔1500航空公司指数下跌近4%，至5月7日以来的最低水平。美国航 空、美联航跌超5%。由于原油价格飙涨，能源、油气和光伏板块提振上行，其中油气板块涨近2.7%。 周五美股三大股指下跌。标普500指数跌破6000 ...

Key Takeaways LLY stock crossed its 50-day SMA, signaling potential bullish momentum after recent underperformance. Mounjaro and Zepbound drove about 48% of Q1 revenues, aided by global launches and supply gains. LLY expects 2025 revenues of $58B-$61B, with growth fueled by Mounjaro, Zepbound and other new drug approvals.Eli Lilly and Company (LLY) has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through i ...

Eli Lilly & Co. LLY may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.Zepbound's Momentum Keeps Eli Lilly In The LeadWith Zepbound continuing to dominate the GLP-1 obesity category and new catalysts on the horizon, JPMorgan sees Eli Lilly as still one of the top picks in the sector.Prescriptions for both Zepbound and Mounjaro are running ahead of expectations in the second quarter, positioning Eli Lil ...

Eli Lilly (LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- and as a result, the stock has taken off, climbing more than 170% in three years.You may recognize the names of these blockbusters driving Lilly's growth, as they've been widely talked about across the media. Lilly sells tirzepatide, commercialized as Zepbound for weight loss and Mounjaro for type 2 diabetes. Do ...

21世纪经济报道记者 唐唯珂 广州报道 有关治疗阿尔茨海默病（AD）的甘露特钠胶囊（GV-971，商品名"九期一"）停产的消息不断。 而实际上甘露特钠货源紧张从半年前就开始了，当时只是供货量减少，最近半个月则完全断货。在网络 销售平台上，药品价格也因供给问题暴涨，原价为每盒（150mg*42粒）296元的甘露特钠胶囊已经涨到 了每盒830元-1033元，且商品大多显示"已卖光"。 该药附条件获批于2019年，目前应正处于换证阶段，此次"断货"或与换证有关。21世纪经济报道记者向 绿谷制药求证甘露特钠胶囊目前的供货情况，是正常换证导致还是未来直接关闭停产，对方表示暂时不 予回复。 根据绿谷制药近期统计，目前，公司400热线电话及在线平台已收到超过9300名患者的求药需求。此 外，公司也连续收到超过1200位医生给绿谷的建议：尽快保障甘露特钠胶囊的供应，保证患者用药连续 性。目前公司正积极与有关部门沟通，审评审批已进入最终阶段，相信患者需求不久后将得到满足。 还有报道称，绿谷制药因现金流极度紧张，已通知全体员工从6月起放假三个月，每月工资降至2600 元。 2019年11月，国家药品监督管理局有条件批准了甘露特钠 ...

礼来替尔泊肽注射液多剂量预装笔在中国上市 智通财经6月12日电，礼来宣布穆峰达（替尔泊肽注射液多剂量预装笔）在中国上市。这是继年初替尔 泊肽成功上市后，礼来推出的新型注射装置，以增加在中国的供应，满足更多患者需求。该多剂量预装 笔每支包含4个固定剂量，每周使用一个剂量。 ...

⼀、公司简介 : 宜明昂科生物医药技术 (01541.HK), 成⽴于 2015 年， 2023 年 9 ⽉在⾹港主板上市，与传统药企不同，宜明昂科主攻 " 免疫系统激活 " ⽅向，开发创新 药物帮助⼈体⾃⾝免疫细胞攻击癌细胞。公司重点产品包括 IMM01( 可激活免疫系统吞噬癌细胞 ),IMM2510 （全球⾸创兼具 " 抑制肿瘤⾎管生成 " 和 " 激活免疫 " 的双特异性抗体药物，即可 同 时 打 击 两种 肿 瘤信号 ）等等其它药品，覆盖的市场包括了肿瘤免疫治疗、⾃⾝免疫疾病和代谢及⼼⾎管疾 病市场。 ⽬前达到 III 期临床的产品管线有 6 个 ： ⼆、管理层及股东： 实⼒ 与商 业化并存 ，礼来等医药基⾦ 领衔 重 仓 创始⼈兼⾸席科学官⽥⽂志博⼠ 持股 约 17% ，拥有 30 多年生物医药⾏业经验，负责公司整体战略、研发⽅向和临床推⾏。 CEO 兼任科学官在同⾏中 极少⻅，⽥博⼠是少数同时精通医学和医药市场运作的⼈才，因此便于公司打通"药物研发→临床→卖给市场"的闭环链条。 公司 其它管理 层 成 员也 ⼤多具 备多年 国 际药 企 （如 辉 瑞、礼来、阿斯利康） 从业或投资 经验。 上海张科 ...

Weight loss syringes of the brands "Wegovy", "Ozempic" are sold at In der Achat Apotheke in Mitte, Germany.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Novo Nordisk's blockbuster weight loss and diabetes drugs Wegovy and Ozempic are once again being linked to unintended side effects. The weekly injections may, in very rare cases, cause a serious eye condition that can ...

Juvena Therapeutics is a platform-driven, clinical-stage company unlocking the therapeutic potential of stem- cell secreted proteins and translating them into a growing pipeline of engineered biologics for chronic muscle and metabolic diseases. Juvena is achieving this through its fully integrated, end-to-end Artificial Intelligence (AI)-enabled drug discovery and development platform, JuvNET, that combines a compounding database mapping secreted proteins to specific disease phenotypes, in silico and in vit ...